LAUSANNE, Switzerland, Nov. 21, 2023 /PRNewswire/ — Legacy Healthcare, a clinical-stage biopharmaceutical company, is making waves in the field of autoimmune and inflammatory diseases with its groundbreaking lead drug candidate, Coacillium. This innovative medicine is transforming the lives of children and adolescents suffering from moderate and severe alopecia areata.
Recent studies presented at the 2023 annual meeting of the European Academy of Dermatology and Venereology (EADV) have shown remarkable results for Coacillium. The groundbreaking topical botanical drug has proven to be highly effective in promoting hair regrowth in children with alopecia areata. Patients using Coacillium have experienced substantial improvements, even after ceasing treatment, while the placebo group showed minimal changes.
Saad Harti, CEO of Legacy Healthcare, praised Coacillium’s success, stating, “Coacillium is among the first drugs to demonstrate sustained remission off-treatment in an autoimmune and inflammatory disease, without any immune-altering side effects.” This achievement is an exciting milestone in the pharmaceutical industry, offering hope to millions of individuals affected by alopecia areata.
Legacy Healthcare firmly believes that Coacillium has the potential to be a blockbuster drug for alopecia areata treatment. The company is committed to further research and development to expand treatment options for patients suffering from autoimmune and inflammatory diseases.
In a podcast with PharmaPhorum, Harti shed light on the history and benefits of botanical drugs in pharma, emphasizing recent regulatory changes that have facilitated their development. He also revealed promising data on Coacillium, which has fueled the drug’s growing reputation as a game-changer in the field.
Legacy Healthcare’s dedication to pioneering botanical drugs is driven by a passion to address the unmet needs of fragile patients, including children, cancer patients, those with chronic conditions, and the elderly. Supported by the Swiss Government, Legacy Healthcare is committed to delivering novel drug candidates that ensure unparalleled safety and provide effective treatment options to those who need them most.
Frequently Asked Questions (FAQ)
1. What is alopecia areata?
Alopecia areata is an autoimmune condition characterized by hair loss. It can occur in both children and adults.
2. What is Coacillium?
Coacillium is a groundbreaking topical botanical drug developed by Legacy Healthcare. It has shown promising results in promoting hair regrowth in children and adolescents with alopecia areata.
3. Has Coacillium been approved for use?
As of now, Coacillium is still in the clinical development stage. It has shown significant potential in trials, but further research and regulatory approval are required before it can be made widely available.
4. Are there any side effects of using Coacillium?
According to Saad Harti, CEO of Legacy Healthcare, Coacillium has demonstrated sustained remission off-treatment without any immune-altering side effects.
5. How does Legacy Healthcare support vulnerable patients?
Legacy Healthcare is dedicated to developing drug candidates that address the unmet needs of fragile patients, including children, cancer patients, individuals with chronic conditions, and the elderly. Their mission is to provide safe and effective treatment options for those who lack satisfactory alternatives.
For additional information, please visit Legacy Healthcare’s official website at www.legacyhealthcare.ch.
Note: The information in this article is based on Legacy Healthcare’s press release and for informational purposes only.